- Home
- AHCO vs TYRA Comparison
AHCO vs TYRA Comparison
Compare AHCO & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHCO
- TYRA
- Stock Information
- Founded
- AHCO N/A
- TYRA 2018
- Country
- AHCO United States
- TYRA United States
- Employees
- AHCO N/A
- TYRA N/A
- Industry
- AHCO Medical/Nursing Services
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- AHCO Health Care
- TYRA Health Care
- Exchange
- AHCO Nasdaq
- TYRA Nasdaq
- Market Cap
- AHCO 1.4B
- TYRA 1.3B
- IPO Year
- AHCO N/A
- TYRA 2021
- Fundamental
- Price
- AHCO $10.85
- TYRA $28.00
- Analyst Decision
- AHCO Buy
- TYRA Strong Buy
- Analyst Count
- AHCO 4
- TYRA 5
- Target Price
- AHCO $11.38
- TYRA $31.00
- AVG Volume (30 Days)
- AHCO 648.6K
- TYRA 176.5K
- Earning Date
- AHCO 11-05-2024
- TYRA 11-05-2024
- Dividend Yield
- AHCO N/A
- TYRA N/A
- EPS Growth
- AHCO N/A
- TYRA N/A
- EPS
- AHCO N/A
- TYRA N/A
- Revenue
- AHCO $3,260,737,000.00
- TYRA N/A
- Revenue This Year
- AHCO $4.40
- TYRA N/A
- Revenue Next Year
- AHCO $5.21
- TYRA N/A
- P/E Ratio
- AHCO N/A
- TYRA N/A
- Revenue Growth
- AHCO 6.05
- TYRA N/A
- 52 Week Low
- AHCO $6.37
- TYRA $10.38
- 52 Week High
- AHCO $11.90
- TYRA $28.79
- Technical
- Relative Strength Index (RSI)
- AHCO 53.57
- TYRA 68.30
- Support Level
- AHCO $10.52
- TYRA $20.30
- Resistance Level
- AHCO $11.10
- TYRA $27.55
- Average True Range (ATR)
- AHCO 0.36
- TYRA 1.41
- MACD
- AHCO 0.07
- TYRA 0.54
- Stochastic Oscillator
- AHCO 81.20
- TYRA 89.45
About AHCO AdaptHealth Corp.
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. It focuses on providing; sleep therapy equipment, supplies, and related services (including CPAP and bi-PAP services) to individuals suffering from obstructive sleep apnea (OSA), medical devices and supplies to patients for the treatment of diabetes (including continuous glucose monitors (CGM and insulin pumps), home medical equipment to patients discharged from acute care and other facilities, oxygen and related chronic therapy services in the home, and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy and nutritional supply needs.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).